QIDP Program Heads Into Uncomplicated Territory: Iterum, Paratek Eye uUTI Indications
Executive Summary
Iterum’ssulopenem is first QIDP candidate to enter Phase III for uncomplicated urinary tract infection; Paratek’sNuzyra could be next.
You may also be interested in...
Iterum Anxiously Awaiting Other Results After SURE 3 Failure
Iterum’s antibiotic sulopenem missed its endpoint by the equivalent of one patient. The company believes the Phase III data could still support its NDA for urinary tract infections.
QIDP Roundup: Familiar Names Dominate 2019 Designations
US FDA's Qualified Infectious Disease Product program is growing slowly, but still growing.
Paratek's Antibiotic Nuzyra Survived 20 Years – Now For The US Launch
Company still mulling pricing for broad-spectrum antibiotic Nuzyra (omadacycline), which is set to launch in the US in the first quarter, following FDA approval Oct. 2.